.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Chubb
Federal Trade Commission
Cipla
Queensland Health
Chinese Patent Office
Teva
Julphar
Cerilliant
Merck

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,034,375

« Back to Dashboard

Which drugs does patent 8,034,375 protect, and when does it expire?


Patent 8,034,375 protects ABRAXANE and is included in one NDA. There has been one Paragraph IV challenge on Abraxane.

This patent has seventy-six patent family members in twenty-five countries.

Summary for Patent: 8,034,375

Title:Combinations and modes of administration of therapeutic agents and combination therapy
Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Inventor(s): Desai; Neil P. (Santa Monica, CA), Soon-Shiong; Patrick (Los Angeles, CA)
Assignee: Abraxis Bioscience, LLC (Los Angeles, CA)
Application Number:11/359,286
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abraxis Bioscience
ABRAXANE
paclitaxel
FOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesYes► Subscribe► Subscribe TREATMENT OF LUNG CANCER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,034,375

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,758,891Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
8,268,348Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
8,735,394Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
9,561,288Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
9,101,543Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
8,257,733Methods and compositions for treating proliferative diseases► Subscribe
7,780,984Methods and compositions for treating proliferative diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,034,375

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
SloveniaEP2481405► Subscribe
SloveniaEP2097078► Subscribe
SloveniaEP1853250► Subscribe
Singapore166775► Subscribe
Russian Federation2013149282► Subscribe
Russian Federation2012106620► Subscribe
Russian Federation2009121568► Subscribe
Russian Federation2452482► Subscribe
Russian Federation2007134571► Subscribe
Portugal2481405► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Mallinckrodt
Accenture
Baxter
Argus Health
QuintilesIMS
Chubb
Express Scripts
Medtronic
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot